75 results about "Prolonged action" patented technology

Method of limiting low excitation, calculating measured impedance of generator terminal by detecting generator terminal voltage and terminal current, when the measured impedance entering low excitation limited impedance circle, the low excitation limits prolong action of 40-60 ms on amplifying excitation current to maintain generator in stable operation situation, the low excitation limited impedance impedance circle covers static stable loss of excitation protection impedance circle to implement seamless connection with generator loss of excitation protection impedance criterion, and prevent the generator in low excitation operation, the low excitation is limited lagging behind the loss of excitation protection action, thereby generator error jump is caused. The invention is used in generator excitation regulation, comparing with former low extitation limiting method, the invention is more visualized, the loss of excitation protection and low excitation are all R-X impedance plane coordinate description and easy to cooperate with each other.

The invention belongs to the technical field of medicines and discloses an itraconazole temperature-sensitive type gel preparation as well as a preparation method and application thereof. The itraconazole temperature-sensitive type gel preparation is composed of the following components in percentage by weight: 0.02-3% of medicines, 0.05-15% of solubilizing agent, 5-50% of gel matrix, 0-15% of biological adhesive, 0.001-2% of preservative, 0-10% of other additives and the balance of solvent. The itraconazole temperature-sensitive type gel preparation can regulate gelatinization temperature by adjusting composition and control drug release rate and degree, can effectively inhibit growth of candida in vitro and can be used for drug administration on skins, eyes, nasal cavity, oral cavity, straight intestine or vaginal mucosa. The itraconazole temperature-sensitive type gel preparation has obvious slow release and biological adhesion property and can prolong action time of medicines on an infection part, realize long-acting treatment, reduce dosage and toxic and side effects and improve patient compliance.

The invention discloses abscisic acid-embedded chitosan nanoparticles and a preparation method thereof. The abscisic acid-embedded chitosan nanoparticles are nanoparticles formed by wrapping aqueous solution of abscisic acid by an embedding material which is formed by dilute solution of acetic acid of chitosan and a crosslinking agent. The preparation method comprises the following steps of: adding the chitosan into the dilute solution of acetic acid to be dissolved, and then adding solution of sodium hydroxide to adjust the pH value to obtain dilute solution of acetic acid of the chitosan; preparing abscisic acid into aqueous solution; preparing the crosslinking agent into aqueous solution; adding the solution of dilute acetic acid of the chitosan into the aqueous solution of abscisic acid, and then adding the aqueous solution of crosslinking agent drop by drop; and fully mixing uniformly to obtain the abscisic acid-embedded chitosan nanoparticles. The method is simple and easy, and has high embedding rate; the obtained embedding nanoparticles have no adhesion, good glomeration and round surface; after the embedding, the abscisic acid can be protected from external interference, and the stability of the abscisic acid can be improved; the abscisic acid is steadily and slowly released, which prolongs action time and strengthens induced resistance effect; and the chitosan serving as a wall material has disease-resistant and induced resistance effects.

The invention discloses an advanced oxidation method for higher COD (Chemical Oxygen Demand) of leachate biological treatment effluent. The deep oxidation method comprises the following steps: feeding H2O2 and PMS as dual oxidants; feeding a CoFe@MgAl-LDH hydrotalcite catalyst for catalyzing the H2O2 and the PMS to generate .OH and SO4<->.; meanwhile, synergizing the PMS with the H2O2 to generate more .OH, prolonging action time, and further oxidizing to remove refractory organic compounds. According to the advanced oxidation method disclosed by the invention, by adopting multiphase catalytic dual oxidants, the problems that a large amount of concentrated solutions are generated in a membrane treatment method which is mainly adopted by an existing advanced treatment method for leachate, a large amount of chemical sludge is generated in an adopted Fenton oxidation process, secondary pollution metal ions are introduced and the like are solved; according to engineering requirements, coagulation also can be adopted for pretreatment before multiphase oxidation. The advanced oxidation method disclosed by the invention is a clean and high-efficiency advanced oxidation treatment method for the leachate; in addition, the treatment cost is controlled, and the treatment effect is guaranteed.

The invention discloses a compound gel preparation used for deferring the release of weedicide, which is confected by the raw materials with the following weight percentage of 15 to 60 percent of modified bentonite, 10 to 50 percent of carboxymethyl cellulose, 15 to 60 percent of the weedicide and 0.1 to 15 percent of water. The invention also discloses a preparation method of the compound gel preparation used for deferring the release of the weedicide. The compound gel preparation of the invention has the advantages of being capable of deferring the release of the weedicide, reducing medicine dosage, prolonging action time, improving the utilization efficiency of the weedicide and relieving the pollution to the environment caused by the weedicide.

The present invention discloses a new type medicine target slowly-releasing carrier material and its preparation process. Said medicine target slowly-releasing carrier material is made up by utilizing attapulgite and Fe3O4. Its principle lies in that it utilizes the large specific surface area and adsorbability of ultrafine high-purity attapulgite and uses it as carrier material of medicine to prolong action time of medicine in interior of human body, raise concentration of local medicine, raise therapeutic effect of medicine and reduce toxic side effect of the medicine, and utilizes magnetization treatment so as to attain the goal of making target administration and controlling release of medicine.

A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.94 times longer; when tested in vivo in Beagle dogs, this new formulation of silymarin presents a smoother concentration-time curve and reaches a continuous release for 72 hours. This invention discloses its preparation method.

The invention provides a sodium alginate polymer which is generated by carrying out a polymerization reaction, which is initiated by free radicals, to sodium alginate with a monomer which contains anunsaturated double bond and an anionic group, and optionally, a crosslinking agent being poly-functionality water-soluble acrylate or acrylamide. Compared with a sodium alginate microsphere embolic agent on market, the sodium alginate polymer, being a carrier, can adsorb and carry a drug in vitro through ions, wherein the sodium alginate polymer is high in drug carrying capacity and can slowly release the drug in vivo, thus increasing local medicine concentration, prolonging action time of the drug, reducing systemic toxicity of the drug and further improving curative effect of the chemotherapy of the embolism. The invention also provides a novel sodium alginate blood vessel embolism chemotherapy composition, in which the sodium alginate polymer, as the embolic agent and medicine, can be co-delivered to a target blood vessel via a catheter, so that the curative effect of the chemotherapy medicine is fully achieved. The product is free of damage on surrounding normal tissue and can reduce relapse of the diseases.

The invention relates to a sustained release preparation of a novel prescription for treating hypertension and the preparing method thereof. The novel prescription comprises a heart selective Beta1 receptor blocker metoprolol and an angiotensin II receptor antagonist (sartan drugs). The sustained release preparation consists of delayed release part and rapid release part, wherein the heart selective Beta1 receptor blocker metoprolol is the delayed release part, with first hour releasing 25-45%, fourth hour releasing 40-75% and eighth hour releasing over 75%; the angiotensin II receptor antagonist (sartan drugs) is the rapid release part, with 45 minutes dissolution over 75%. The composition has both rapid and prolonged action. The invention discloses in vitro drug release characteristics and preparation method thereof.

The invention relates to the preparation technology of anti-corrosion additives, and aims at providing a preparation method of a corrosion inhibitor loading structure with a large load capacity. The method comprises the following steps: a polystyrene (PS) microsphere emulsion is dispersed into absolute ethyl alcohol, hexadecyl trimethyl ammonium bromide powder, deionized water, ethyl alcohol, and ammoniacal liquor are added with continuous stirring, tetraethyl orthosilicate is added dropwisely for carrying out a reaction, and pumping filtration, cleaning, drying and roasting are carried out in order to obtain hollow silicon dioxide microspheres; absolute ethyl alcohol and hollow silicon dioxide microspheres are added into an acidic solution of cerium nitrate, heating is carried out with stirring, and centrifugation, washing and drying are carried out in order to obtain a final product. Hollow silicon dioxide microspheres are used for loading a corrosion inhibitor, so that direct contact between the corrosion inhibitor and paint is avoided; a mode for improving the amount of the silicon dioxide microsphere loading structure is used in order to increase addition of the corrosion inhibitor, increase the content of the corrosion inhibitor in a coating, and prolong action time of the corrosion inhibitor. The method can be used for effectively solving bad influences on paint stability due to high addition of the corrosion inhibitor in the prior art.

The invention provides a gel matrix and a preparation method thereof, and the gel matrix is used for preparation of gel dosage form drugs. The gel matrix provided by the invention includes: 0.5-10% of gel, 0.1%-10% of a tissue stabilizer, 0.1%-10% of a tissue repair agent, 0.5%-5% of a transdermal enhancer, 1%-10% of a non-water solvent with concentration higher than 90% and water, or a non-water solvent with concentration not more than 50%. The gel matrix provided by the invention has certain leveling property (uniformity), flexibility and moisture retention, so as to reduce the ''parching'' phenomenon. The gel matrix provided by the invention has strong ability of bearing and releasing drugs to satisfy quantitative addition of medicinal ingredient and guarantee stability and uniformity of drug storage and drug concentration in a course of treatment. The gel matrix provided by the invention can improve release rate, percutaneous absorption rate and safe treatment of the drug. The invention can increase tissue compatibility of the preparation, properly prolong action time and application frequency, so as to increase effectiveness and reduce the occurrence of local side effects.

The invention relates to a preparation method of a high-efficiency anti-mildew and anti-bacterial slow-release agent for leather shoes. The present invention selects the mixture of thiocyanate and isothiazolinone to form the high-efficiency leather shoes mildew-proof and antibacterial agent. The agent has the characteristics of low toxicity, high efficiency, and broad spectrum, and can be widely used in various fields such as leather, export leather shoes, wood, coatings, etc., and is an environmentally friendly high-efficiency anti-mold and antibacterial agent. Compared with the original antifungal agent, the prepared agent has enhanced its water solubility by utilizing the excellent inclusion and sustained release effect of cyclodextrin on drugs, as well as the natural biocompatibility of cyclodextrin and leather. , The second is that the agent has a slow-release effect, which can greatly prolong the action time of the anti-fungal agent; the third is to reduce the corrosiveness, toxicity and irritating odor of the anti-fungal agent.

The present invention relates to pharmaceutical compositions comprising a peptide that stimulates the release of gonadotropins and sexual steroids. More specifically, the present invention provides pharmaceutical compositions comprising kisspeptin, preferably in the kp-10 form, or derivatives thereof, for use in ovulation cycle inducing and / or infertility treatment programs. The formulations according to the present invention belong to two main groups: injectable solutions and implantable formulations. The injectable solutions according to the present invention can be divided into immediate release solutions and prolonged action solutions. The implantable formulations according to the present invention can be prepared using an RTV silicone elastomer, a rapid vulcanization silicone elastomer or a rapid vulcanization silicone elastomer with a release modulator.

The invention provides a water-soluble cyclodextrin derivative clathrate of fluorouracil, and an in-situ gel film agent containing the clathrate and having biological adhesion and a preparation method thereof. According to the invention, cyclodextrin derivative-hydroxypropyl-beta-cyclodextrin is used to include fluorouracil hardly soluble in water so as to allow the solubility of fluorouracil in water to be improved and fluorouracil to have a slow release effect, so the in-situ gel film agent is prepared; the in-situ gel film agent is a novel cavity drug delivery preparation and comprises the hydroxypropyl-beta-cyclodextrin clathrate of fluorouracil, a temperature-sensitive gel skeletal material and a biologically adhesive material. The preparation is a freely flowable solution before usage, rapidly forms a gel film on the surface of a cavity, has a great drug release area, good biological compatibility and good gel strength and biological adhesion, is capable of firmly adhering on the mucous membrane of the cavity, prolongs action time, realizes uniform drug distribution, is beneficial for absorption of the drug and diffusion of the drug to peripheral tissue and improves bioavailability and treatment effects of the drug.

The invention relates to a sustained-release preparation of compound metformin hydrochloride rosiglitazone and a preparation method thereof; wherein, rosiglitazone and metformin hydrochloride have slow releasing characteristic in an in-vitro dissolution test, the rosiglitazone is released by 10-30 percent for a first hour, and is released by 60-80 percent for a fourth hour, and is released by morethan 80 percent for an eighth hour; the metformin hydrochloride is released by 15-40 percent for a first hour, is released by 50-70 percent for a fourth hour, and is released by more than 75 percentfor an eighth hour. The formula is mild and has prolonged action of glucose reduction, so as to avoid adverse reaction such as hypoglycemia and gastrointestine malaise, reduce taking times (one or twotimes each day), and improve compliance of a patient. The invention discloses the in-vitro drug-releasing characteristic of the sustained-release preparation and the preparation method thereof.

The invention provides a novel multilayer coating system enteric preparation for dexlansoprazole. The preparation comprises a drug layer I, a drug layer II, enteric coating layers IV and isolating layers III, wherein the isolating layers III are arranged among the drug layer I or II and the enteric coating layers IV, the drug layer I and the drug layer II are respectively composed of dexlansoprazole, a filler, a binder, a stabilizing agent and a lubricant, and the preparation comprises, from interior to exterior, the drug layer I, the isolating layer III-1, the enteric coating layer IV-1, the isolating layer III-2, the drug layer II, the isolating layer III-3 and the enteric coating layer IV-2. The novel multilayer coating system enteric preparation for dexlansoprazole provided by the invention can improve the acid inhibition effect of dexlansoprazole and prolongs action time of dexlansoprazole, the isolation effect of the isolating layers in the whole preparation system is optimized, and stability of product quality is ensured; and a preparation method provided by the invention is applicable to industrial production and has a great application value.

Disclosed herein is the method for synthesis and separation of enantiospecific isomers of floxacins. These isomers can be used to study the antibacterial action, as well as cardiac effects, such as arrhythmogenic activity, QT internal prolongation and dispersion, and Ikr inhibition in humans. A method for the identification of chiral isolates of the floxacins that are devoid or possess less QT prolonging action and thus cause less arthropathy especially of the Torsades de pointes variety. Also disclosed are methods for assaying these isomeric compounds present in the biological fluids.

The invention relates to a kind of lubricating and anti-friction multiphase material as well as its preparing method, especially the new type material that uses the heat proof thermoplastic medlin as the frame material being filled with grease. The invention adopts heat proof thermoplastic medlin as the frame and high drop point grease as the lubricant. The grease is put into the pore of the material by high temperature vacuum permeating method to form the lubricating and anti-friction multiphase material. The grease is enveloped inside to prevent its expire by oxidation; during the rubbing process, the grease can form steady lubricating membrane by the discrepancy of thermal expansion quotient and centrifugation; besides, the constant renewal of the rubbing surface ensured the prolonged action of the grease to fulfill the working conditions of high temperature and high speed.

The invention belongs to the technical field of dyeing auxiliary agents and discloses an efficient fabric carrier. A nano material is prepared from nano hydroxyapatite, sodium alginate and the like; positive ion groups are introduced in a reaction process by adding of 3-chloro-2-hydroxypropyl-trimethyl ammonium chloride and 2,3-glycidyl trimethyl ammonium chloride; gel generated directly or indirectly is used for storage of controlled-release dyes and other components to prolong action time, and by a regulation effect on internal charges, the dye uptake is increased, and the migration propertyis diminished; a polyurethane component is prepared from polyether glycol, dimethylol propionic acid, diethylene glycol and the like; a hydrophobic network is constructed by means of oxime bond self-repairing, ketone-hydrazine crosslinking and the like and used for improving washing resistance and keeping dye components. By the efficient fabric carrier, problems of low washing resistance and highmigration property of an existing common carrier are solved.

The invention discloses graphene nano-silver lidocaine slow-release antibacterial gel. The preparation method comprises the following steps: performing supersonic decomposing on single-layer grapheneoxide in deionized water so as to obtain an aqueous solution of nano graphene oxide; adding silver nitrate and a reducing agent into the aqueous solution of nano graphene oxide so as to obtain nano-silver graphene oxide Ag-nGO; mixing the nano-silver graphene oxide and lidocaine to obtain an Ag-nGO-lido mixture; and dissolving Carbomer 940, PEG400 and glycerin into deionized water, enabling the Carbomer 940 to be fully dispersed at a normal temperature, dissolving the Ag-nGO-lido into the dispersed solution after dispersing, adding sodium hydroxide and potassium sorbate to be dissolved, supplementing deionized water, and fully mixing, thereby obtaining the product. The graphene nano-silver lidocaine slow-release antibacterial gel disclosed by the invention has the beneficial effects that the lidocaine is adsorbed onto the surface of a nano-carrier, is slowly released and has effects of obviously prolonging action time of the lidocaine and enhancing transdermal effects of drugs; a graphene composite nano-silver material serves as a carrier, the graphene and silver ions have antibacterial effects, particularly the silver ions have excellent antibacterial abilities and do not have drug tolerance, and risk of infection caused by long-term retention catheterization can be reduced.

The invention designs and synthetizes a lead compound by using a glycyrrhetinic acid derivative as a carrier and being connected with norcantharidin and a derivative thereof through ester bonds, the obtained lead compound expects to have the advantages of having liver targeting action, prolonging action time, reducing toxic and side effects and improving the curative effect of resisting liver cancer, and a model compound is provided for the research of a liver targeting medicine for the liver cancer. Firstly, two positions of C11 and C30 in glycyrrhetinic acid molecules are reduced and synthetized respectively, methyl ester is chemically modified into glycyrrhetinic acid (GA) and 18 alpha-glycyrrhetinic acid as well as a derivative thereof, the glycyrrhetinic acid (GA) and 18 alpha-glycyrrhetinic acid as well as the derivative thereof are used as framework molecules, through a series of reactions, the framework molecules and the norcantharidin (NCTD) as well as a derivative thereof are condensed to form ester as a prodrug, a cell activity screening test is performed on 5 object compounds, 13 object compounds in 3 series are synthetized, and structural characterization is performed on a carbon spectrum, a hydrogen spectrum and a mass spectrum; the influence of different concentrations of 5 object compounds on HepG2 cell proliferation of the liver cancer is inspected by a method, results show that inhibitory action presents time-dose dependence, and the suppression ratio of 14 mu g / mL is the highest.

The present invention discloses a doxycycline hydrochloride liposome gel preparation. It is made up by uniformly mixing (by wt%) 20-80% of doxycycline hydrochloride liposome and 80-20% of gel matrix. The invented doxycycline hydrochloride liposome gel preparation can be used as local antibiotic medicine, and can effectively prolong action time of medine and can raise antibacterial effect of medicine.

The invention relates to the technical field of medicine, in particular to a traditional Chinese medicine compound gel for treating osteoporosis, which comprises medicine, macromolecule matrix material, dissolvent, humectant and preservative and can also comprise neutralizing agent and transdermal enhancer, wherein the medicine include unprocessed radix aconite extract, datura flower extract, clematis chinensis extract, common clubmoss herb extract and a small quantity of camphor and muskiness, the macromolecule matrix material can be selected from carbopol, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, hydroxy propyl cellulose and polyvinylpyrrolidone, the dissolvent is water, the humectant is glycerin, the preservative can be selected from hydroxyphenyl ethylester, benzalkonium bromide and EDTA-Na, the neutralizing agent can be selected from sodium hydroxide or trolamine, and the transdermal enhancer can be selected from azone, limonene and propanediol. The traditional Chinese medicine compound gel is applied through skin, thus avoiding stomach and intestinal irritation caused by oral administration, reducing the whole body blood concentration and toxic side effects, prolonging action time, reducing medicine application time and increasing the medicine application compliance of a patient.

The invention discloses abscisic acid-embedded chitosan nanoparticles and a preparation method thereof. The abscisic acid-embedded chitosan nanoparticles are nanoparticles formed by wrapping aqueous solution of abscisic acid by an embedding material which is formed by dilute solution of acetic acid of chitosan and a crosslinking agent. The preparation method comprises the following steps of: adding the chitosan into the dilute solution of acetic acid to be dissolved, and then adding solution of sodium hydroxide to adjust the pH value to obtain dilute solution of acetic acid of the chitosan; preparing abscisic acid into aqueous solution; preparing the crosslinking agent into aqueous solution; adding the solution of dilute acetic acid of the chitosan into the aqueous solution of abscisic acid, and then adding the aqueous solution of crosslinking agent drop by drop; and fully mixing uniformly to obtain the abscisic acid-embedded chitosan nanoparticles. The method is simple and easy, and has high embedding rate; the obtained embedding nanoparticles have no adhesion, good glomeration and round surface; after the embedding, the abscisic acid can be protected from external interference, and the stability of the abscisic acid can be improved; the abscisic acid is steadily and slowly released, which prolongs action time and strengthens induced resistance effect; and the chitosan serving as a wall material has disease-resistant and induced resistance effects.

The invention relates to a slow release type insect pest attractant microcapsule and a preparation method thereof. The microcapsule disclosed by the invention is composed of a capsule wall and a capsule core which contains insect pest attractant. The preparation method thereof comprises the following steps of: mixing the capsule core containing the inset pest attractant, an emulsifier and deionized water in certain mass ratio, and stirring for 4-7min at a rotating speed of 350-650r / min, so as to obtain O / W (oil in water) solution; adding capsule wall oil phase into the O / W solution, regulating pH to be 2.7 with hydrochloric acid solution with the concentration of 1.5-2.5mol / L, and shearing for 3-5min at the speed of 8000-11000r / min by adopting a high-speed shearing machine; and reacting the obtained emulsion at the rotating speed of 350-600r / min at the temperature of 38-42 DEG C, filtering, and carrying out vacuum drying. The insect pest attractant microcapsule prepared by the invention is easy to store, has good slow release performance and can effectively prolong action time of the inset pest attractant.

Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.

The invention relates to a panax notoginseng saponins sustained-release gel and a preparation method thereof and relates to the field of medicine health care. The panax notoginseng saponins sustained-release gel comprises, by weight ratio, 56-74% of carboxymehyl chitosan, 7.4-16.6% of polyvinylpyrrolidone, 0.07-0.11% of panax notoginseng saponins and 18.4-27.7% of coss-linking agent. The medicine release rate of panax notoginseng saponins is effectively controlled, the panax notoginseng saponins utilization rate is improved, metabolism dynamics properties of the medicine in the human body are improved, too high medicine concentration in blood is avoided, and a stable plasma concentration is provided, so as to achieve the objectives of prolonging action time of the medicine in the human body and reducing dosing times; toxic and side effects of the medicine can further be reduced, and patients' compliance is improved.

The invention discloses a novel paliperidone polyethylene glycol conjugated prodrug (PEG-paliperidone) and relates to preparation and an application of the paliperidone polyethylene glycol conjugated prodrug. The general formula of the PEG-paliperidone is shown in the description; the PEG-paliperidone comprises a carrier (polyethylene glycol, PEG), a connecting arm (AA) and paliperidone, wherein the carrier is single-arm polyethylene glycol, double-arm polyethylene glycol and four-arm polyethylene glycol, and the polymerization is 10-500 degrees; the connecting arm is an amino acid or oligopeptides comprising the amino acid. The paliperidone is subjected to PEGylation transformation, the half-life period of the medicine is prolonged and reaches 1 time per week or even 1 time per month, the use compliance is improved; the water solubility of the medicine is improved, the novel paliperidone polyethylene glycol conjugated prodrug can be prepared into a common injection, the ultra-hard process using a nanocrystalline prolonged action preparation is avoided, and the production difficulty and the use risk are reduced. The preparation process is simple in operation, is green and environmentally friendly, is low in cost, and is easy to realize industrial production. The general formulas of the single-arm polyethylene glycol, the double-arm polyethylene glycol and the four-arm polyethylene glycol are as shown in the description.

Miticide composition of prolonged action against Varroa destructor of bees comprising oxalic acid, glycerin, 4-carbon dicarboxylic acid and formic acid and its manufacturing process. A cellulose trip impregnated in said miticide composition, which is introduced in the bee hives and its manufacturing processes.